2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Omics Technologies, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Biological Therapies, Checkpoint Inhibitor, Women’s Health, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Bleeding and Clotting, Platelet Disorders, Thromboembolism, Thrombotic Disorders, Immunology, Research, Fundamental Science, Translational Research, Study Population, Human, Adult, Animal Model
PAPER

4825 A novel minimally invasive method for single-cell profiling of human large-vessel endothelium reveals endothelial activation in antiphospholipid syndrome

Sumith R Panicker, PhD, Delong Liu2, Ecem Sevim, MD3, Gustaf Wigerblad, PhD4, Yogendra Kanthi, MD5
1 National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland, United States
2 Office of Biostatistical Research, NHLBI, NIH, Bethesda, Maryland, United States
3 National Institute of Arthritis, Musculoskeletal and Skin Disorders, NIH, Bethesda, Maryland, United States
4 NIAMS, NIH, Bethesda, Maryland, United States
5 National Heart, Lung and Blood Institute, National Institutes of Health, National Institutes of Health, Bethesda, Maryland, United States

INTRODUCTION

Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by circulating autoantibodies against cell-surface phospholipids and phospholipid-binding proteins. Clinical manifestations include arterial and venous thrombosis, pregnancy morbidity, and widespread microvascular disease. Although endothelial dysfunction is central to APS pathogenesis, comprehensive profiling of human endothelial cells (ECs), particularly from large vessels, has been limited by lack of clinically feasible methods to obtain viable, representative ECs from intact vessels. In this study, we developed a novel, minimally invasive protocol for rapid, high-yield isolation of ECs from the brachial vein and performed single-cell RNA sequencing (scRNA-seq) to define normal endothelial heterogeneity and investigate endothelial pathobiology in APS.

HYPOTHESIS

Large-vessel ECs from patients with APS exhibit an activated phenotype with a distinct transcriptomic profile.

METHODS

Using a minimally invasive sampling procedure, J-wires were introduced through venous catheters to gently scrape ECs from the brachial veins of 7 patients with primary APS and 8 healthy volunteers. ECs were purified using an antibody-based negative selection strategy and subjected to scRNA-seq. Data were analyzed using Seurat v5.5. VWF (+), PTPRC (-) cells were annotated as ECs for downstream analyses. Differentially expressed genes (DEGs) identified by single-cell analysis were further validated using pseudo-bulk analysis with DESeq2 package.

RESULTS

Across experiments, the purification protocol yielded sufficient ECs for scRNA-seq. Immunofluorescence microscopy confirmed purified cells as ECs (CD146 (+), CD45 (-)). Following sc-RNAseq and quality-control filtering, the purified cell population was >80% ECs, with a median yield of 4,434 ECs per participant. Notably, the ECs population expressed ACKR1, a gene shown to be highly expressed in venous endothelial cells.

Uniform Manifold Approximation and Projection identified seven clusters, with most ECs concentrated in Cluster0 (47%) and Cluster1 (42%). Multiple genes known to be expressed in venous ECs including ACKR1, AQP1 and PLVAP were more abundant in Cluster 0 than Cluster1. Within healthy ECs, Cluster1 exhibited enrichment of pathways related to hemostasis, innate and adaptive immune responses, interferon signaling, and VEGFA–VEGFR2 signaling compared to Cluster0, indicating transcriptomic heterogeneity among ECs within the same vascular bed.

Comparison of total APS ECs with healthy ECs (log₂FC > 0.75; adjusted P < 0.05) identified 27 DEGs, including upregulation of SERPINE1 and downregulation of IFI27. Elevated circulating SERPINE1 (PAI-1) levels have been previously observed in APS, supporting the biological relevance of this finding. Notably, brachial vein ECs expressed approximately two-fold higher levels of SERPINE1 suggesting large-vein ECs as a potential major source of circulating PAI-1 in APS.

Gene set enrichment analysis across multiple pathway databases demonstrated enrichment of pathways related to extracellular matrix organization (EMO), epithelial–mesenchymal transition (EMT), and TGF-β/SMAD signaling in APS ECs. Cluster-specific comparisons identified 45 and 28 DEGs in Clusters 0 and 1, respectively, with nine genes shared between clusters. Pseudo-bulk analysis (log₂FC > 0.75, adjusted P < 0.05, baseMean > 10) identified 451 upregulated and 158 downregulated genes in APS. Upregulated pathways were associated with EMO, EMT, cell adhesion, and TNF-α signaling, whereas interferon signaling pathway was downregulated, potentially reflecting the effects of prescribed immunomodulatory therapy. Collectively, these findings indicate an activated endothelial phenotype in APS.

SUMMARY

We describe a novel, minimally invasive, rapid, high-yield method for isolating endothelial cells from large vessels that enables direct investigation of endothelial biology in vivo across a range of vascular diseases, including APS. Our single-cell transcriptomic analysis revealed substantial endothelial heterogeneity within the same vascular bed. Differential gene expression and pathway analyses further reveal a procoagulant and proinflammatory endothelial phenotype in APS, providing new insights into disease pathogenesis.
Sumith R Panicker, PhD: No relevant conflicts of interest to declare.